Table 5.
Vaccinations (last dose) prior to index date* as explanatory variables in intussusception cases (BC level 1) and matched controls; comparison among study groups (n = 388)
| Exposurea | Cases (n = 116)n/N (%) | Population-based controls (n = 272)n/N (%) | Univariate matchedb logistic regression analysis(OR + 95% CI, p value) |
|---|---|---|---|
| Rotavirus life vaccine | |||
| Dose 1 | 11/116 (9.5) | 9/272 (3.3) | 5.94 (1.58–22.35) p = .0084 |
| Dose 2 | 30/116 (25.9) | 73/272 (26.8) | 0.80 (0.46–1.38) p = .4164 |
| Dose 3 | 15/116 (12.9) | 37/272 (13.6) | 0.92 (0.46–1.85) p = .8091 |
| Hexavalent (DTPa-IPV-Hib-Hep-B)c vaccine | |||
| Dose 1 | 16/116 (13.8) | 19/272 (7.0) | 2.64 (1.14–6.13) p = .0234 |
| Dose 2 | 19/116 (16.4) | 44/272 (16.2) | 0.86 (0.43–1.71) p = .6623 |
| Dose 3 | 64/116 (55.2) | 138/272 (50.7) | 1.20 (0.73–2.28) p = .3825 |
| Dose 4 | 0/116 (0.0) | 1/272 (0.4) | Calculation of OR not possible, p = .9917 |
| Pneumococcal conjugate vaccine | |||
| Dose 1 | 17/116 (14.7) | 23/272 (8.5) | 2.33 (1.04–5.21) p = .0390 |
| Dose 2 | 17/116 (14.7) | 45/272 (16.5) | 0.78 (0.39–1.53) p = .4652 |
| Dose 3 | 64/116 (55.2) | 141/272 (51.8) | 1.18 (0.67–2.08) p = .5588 |
| Dose 4 | 0/116 (0.0) | 1/272 (0.4) | Calculation of OR not possible, p = .9917 |
| Meningococcal C vaccine | |||
| Dose 1 | 4/116 (3.5) | 4/272 (1.5) | 3.43 (0.75–15.75) p = .1134 |
| Dose 2 | 2/116 (1.7) | 7/272 (2.6) | 0.68 (0.13–3.65) p = .6541 |
n number of participants exposed; N total number of participants with available information; BC Brighton Collaboration criteria for intussusception; level 1 highest level of diagnostic certainty; * index date cases: date of symptom onset, controls: day of life on which the matching case experienced first symptoms of intussusception; a German National Immunization Program: In Germany, rotavirus vaccines may be administered from the age of 6 weeks with at least 4 weeks between the doses 1, 2, and 3, whereas hexavalent and pneumococcal conjugate vaccines may be given from the age of 8 weeks with at least 4 weeks between the doses 1, 2, and 3. Rotavirus, hexavalent, and pneumococcal conjugate vaccines may be administered concomitantly. Meningococcal vaccines may be given from the age of 11 months, if desired, concomitantly with hexavalent and pneumococcal vaccine doses 4. bmatched by gender, date of birth (± 30 calendar days), federal state, and place of residence (first digit of the zip code); ctetanus, diptheria, acellular pertussis, polio (inactivated), Haemophilus influenzae type B, hepatitis B.